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Abstract 
Identifying potential therapeutic targets for aggressive cancers is critical to minimizing 
side effects of treatments and ultimately increasing patient treatment compliance. Here 
we demonstrate that kinesin motor protein Kif18A has the potential to serve as a minimally 
toxic target for the treatment of cancers such as triple negative breast cancer (TNBC) and 
colorectal cancer (CRC). Kif18A inhibition reduces the proliferation of multiple TNBC cell 
types and one CRC cell type. While endogenous Kif18A expression does not seem to 
indicate cell type specific sensitivity to Kif18A inhibition, the expression levels are higher 
in cancer cells than in normal somatic cells. Modal chromosome number has the 
strongest correlation with cell sensitivity to Kif18A depletion, indicating that Kif18A is 
heavily involved in the regulation of mitotic progression for cells with chromosomal 
instability. Furthermore, cells with chromosomal instability appear to arrest in mitosis and 
form multipolar spindles upon Kif18A knockdown. Based on these data, Kif18A may serve 
as a novel therapeutic target for aggressive, chromosomally unstable cancers because 
of its role in regulating mitotic spindle dynamics to promote successful progression 
through mitosis.   
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Background 
Aggressive cancers are often treated with generalized therapies such as radiation 
and chemotherapy that have limited success against the molecularly diverse factors 
causing cancer proliferation and metastasis. There is an urgent need for more targeted 
therapeutic options to allow for specialized, individual treatments against the vast array 
of cancer molecular subtypes. Triple negative breast cancer (TNBC), a subtype of breast 
cancer affecting approximately 15% of all breast cancer patients, is an example of a 
particularly lethal cancer [10]. TNBC is common in younger women and is often treated 
with a combination of surgery, radiation, and chemotherapy. TNBC acquired its name 
because it lacks three cellular features that are common therapeutic targets for breast 
cancer therapy: the estrogen receptor, the progesterone receptor, and the overexpression 
of the HER2 receptor [2] (Figure 1). The aggressive nature of the disease combined with 
the lack of available targeted therapies contributes to the poor outcomes of TNBC 
patients: the median survival is less than one year [2]. Another example of an aggressive 
cancer with few targeted therapeutic options is colorectal cancer (CRC), which is currently 
the second most lethal cancer in the United States [6]. Much like TNBC, colorectal cancer 
is often treated with a combination of surgery, radiation, and general chemotherapies. 
Cancers such as TNBC and CRC highlight the necessity of researching therapeutic 
targets and strategic approaches to halt cancer progression with minimal side effects.  
Traditional cancer therapies target proteins and pathways involved in cell division, 
with the goal of preventing the cancer cells from multiplying. Unfortunately, these 
therapies often affect the division of normal cells as well, leading to negative side effects 
that may prevent a patient from continuing a course of treatment. Developing a therapy 
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that specifically inhibits cancer cell viability requires isolating differences between cancer 
cells and non-cancerous cells. One such difference that is present in most aggressive 
cancers is genomic instability in the form of either chromosomal instability (CIN) or 
microsatellite instability (MSI). Chromosomal instability, or the duplication or deletion of 
either whole chromosomes or pieces of chromosomes, leads to variable numbers of 
chromosomes within a cell [1]. Microsatellite instability, or genomic damage from errors 
in DNA repair mechanisms, can cause over- or under expression of certain genes and 
pathways. The genomic instability in CIN and MSI cancer cells may cause an increased 
reliance on the careful regulation of cell division for successful propagation; therefore, 
regulators of cell division might serve as novel therapeutic targets for aggressive cancers 
such as CRC and TNBC.   
One promising class of mitotic regulator proteins is the kinesin family. Kinesins are 
ATP-dependent motor proteins that travel along microtubules and aid in intracellular 
transport of other proteins. Several types of kinesins also assist with regulating 
microtubule dynamics, or the lengthening and shortening of microtubules. One kinesin in 
particular, Kif18A, regulates the dynamics of microtubules that form the mitotic spindle, a 
structure that aligns and separates chromosomes during mitosis. The structure of Kif18A 
includes a motor domain at the N-terminus, a microtubule binding domain within the C-
terminus, and a protein binding domain within the C-terminus [7]. Within the protein 
binding domain, there is a highly conserved region that binds protein phosphatase 1 
(PP1), which is a serine/threonine protein phosphatase that is important for cell growth 
and proliferation [4]. The PP1 binding region is important for stabilizing proper 
attachments between microtubules and kinetochores, leading to proper mitotic 
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progression [8]. Within the motor domain of Kif18A, a surface loop has been verified to 
be important for attenuating microtubule movements, and thus contributing to proper 
chromosome alignment [7]. Consequently, Kif18A has been shown to be instrumental in 
the proper alignment of chromosomes during metaphase of mitosis [17].  
Several studies have found that Kif18A is significantly overexpressed in colorectal, 
breast, liver, and several other cancers, and that a higher Kif18A expression level 
correlates with increased metastasis and a worse prognosis [5,11,12]. Depletion of Kif18A 
in germline cells has a detrimental effect to the cells, causing mitotic arrest and eventual 
apoptosis; interestingly, Kif18A depletion in somatic cells does not produce a mitotic 
arrest [3]. In both germline and somatic cells, Kif18A depletion disrupts proper 
chromosome alignment during metaphase. These data suggest that while all cells may 
require Kif18A for chromosome alignment, only certain cells require Kif18A for mitotic 
progression and proliferation. This cell-specific sensitivity to Kif18A-depletion must be 
further investigated to determine which types of cells require Kif18A and to elucidate why 
certain cells require this kinesin more than others.  
 
  




Two immortalized TNBC cell lines (MDA-MB-468 and MDA-MB-231) and four 
immortalized colorectal cancer cells (HCT116, HT29, LoVo, LS1034) were cultured at 
37oC and 5% CO2. The MDA-MB-468, MDA-MB-231, LoVo, and HT29 cell lines were 
cultured in DMEM/F12 media with 10% fetal bovine serum (FBS) and 1% antibiotics 
(Penicillin/Streptomycin). HCT116 cells were cultured in McCoy’s 5A media with 10% 
FBC and 1% Penicillin/Streptomycin. All cell lines were passaged every 48 hours.  
Proliferation Assay 
Cells from four different cell lines (MDA-MB-231, MDA-MB-468, LoVo, HCT116) 
were seeded in a 12 well plate at approximately 150,000 cells per well. The cells were 
allowed to settle on the plate for 24 hours before being transfected with either scrambled 
sequence control short interfering RNA (siRNA) or kinesin-specific siRNA for either 
Kif18A, Kif4A, KID, or MCAK. Two types of Kif18A siRNA targeting different regions of 
the Kif18A mRNA transcript were obtained from Invitrogen, and the sequences will be 
referred as “Kif18A #3 siRNA” (5’ GCU GGA UUU CAU AAA GUG GdTdT3’) and “Kif18A 
#4 siRNA” (5’ GCU UGU UCC AGA AUC GAG AdTdT 3’). SiRNA transfection was carried 
out by combining 5 picomoles of each siRNA with 1.5 uL RNAiMax (Thermo Scientific) 
and incubating for 10 minutes before adding to cells.  
Approximately eight hours after siRNA transfection, cells from each condition were 
transferred to a 96 well plate coated with 50 ug/mL collagen I at a density of 2,000 cells 
per well. The cells were then imaged every two hours for 120 hours using high contrast 
brightfield microscopy. The cells were incubated in a Biospa system from BioTek at 37oC 
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and 5% CO2 between image acquisitions. For two additional cell lines (HT29 and 
LS1034), cells were seeded in a collagen-coated 24 well plate at a density of 10,000 cells 
per well, allowed to settle on the plate for 24 hours, and then transfected with either control 
or Kif18A siRNA as described above but imaged in the 24 well plate. The reasoning 
behind this protocol change was that the 24 well plate provided adequate replicates for 
acquiring statistical power with less handling of the cells. All cell lines were performed 
with three experimental independent replicates.  
Immunofluorescence Staining 
Cells were seeded onto coverslips in a 24-well plate at 80,000 cells per well and 
treated with control or Kif18A siRNA using the protocol described above. Approximately 
48 hours after siRNA treatment, coverslips were fixed with -20oC cold methanol for 5 
minutes and washed three times in Tris Buffered Saline (TBS), pH 7.4. The coverslips 
were then blocked with 20% goat serum in antibody diluting buffer (Abdil; TBS, pH 7.4, 
1% BSA, 0.1% Triton X-100, and 0.1% sodium azide) for one hour at room temperature 
while shaking, then washed twice with TBS, and incubated for three hours at room 
temperature with primary antibodies: 2 µg/mL mouse α-tubulin (DM1α), 2.5 µg/mL human 
anti-centromere antibodies (ACA), and 1 µg/mL rabbit Kif18A. The cells were once again 
washed twice with TBS, followed by an hour long, room temperature incubation in 1 ug/mL 
secondary antibodies against mouse, human and rabbit IgG conjugated to Alexa Fluor 
488, 594, and 647 (Molecular Probes). The coverslips were washed three times with TBS 
and mounted onto glass slides with Prolong Gold anti-fade mounting medium with DAPI 
(Molecular Probes).  
 
 Marquis, C.  
 9 
Mitotic Timing 
Cells were seeded at 80,000 cells per well in a four-chambered, glass bottom 
filming dish coated with 50 ug/mL collagen I. Either control or Kif18A siRNA was added 
to two of the four wells after the cells had settled for 24 hours. After an additional 24 hours, 
the original culture media was replaced with CO2-independent media and the cells were 
imaged every two minutes for 16 hours using differential interference contrast (DIC) 
microscopy. To quantify mitotic timing, the amount of time between nuclear envelope 
breakdown and anaphase-entry was recorded for each cell along with qualitative 
observations, such as whether the cell failed to exit mitosis or completed a multipolar 
division. 
Microscopy 
Proliferation Assays were performed on a Cytation microscope (BioTek) with an 
automated BioSpa system (BioTek). Brightfield and phase contrast images were acquired 
with a 4X objective. The Cytation microscope is driven by Gen5 software (BioTek). Fixed 
cells and live mitotic timing assays were imaged using a Ti-E inverted microscope (Nikon 
Instruments) with Nikon objectives Plan Apo 20X DIC N2 0.75 NA with a Spectra-X light 
engine Lumencore) and environmental chamber at 37oC. To capture images, a Clara 
cooled charge-coupled device (CCD) camera (Andor) was used. The Ti-E microscope is 
driven by NIS Elements software (Nikon Instruments). 
Proliferation Assay Data Analysis  
A Gen5 software program from BioTek was used to count cells based on light 
intensity differences between the cells and the background. Automatic image pre-
processing enhanced the light intensity differences between the background and the cells 
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to create images with dark backgrounds and bright cells. Cell counting parameters were 
specified through the Gen5 software program for each cell line based on cell size. A 
validation assay comparing cell counts by Gen5 analysis of high contrast brightfield 
images and DAPI staining showed no significant difference in cell counts, even with 
variations in cell density and treatment condition (Figure 2). 
Knockdown Quantification (Protein Levels) by Immunofluorescence  
The knockdown efficiency was measured using immunofluorescence microscopy. 
Cells from each proliferation assay were plated on coverslips, and fixed and stained as 
described above. Images were captured for Kif18A, α-tubulin, and ACA-labeled 
kinetochore staining. To quantify the amount of Kif18A protein in cells, a circle was drawn 
to encompass the kinetochores in ImageJ, then overlaid onto the Kif18A fluorescent 
channel. The average Kif18A fluorescence intensity was measured for this circle, as well 
as for a reference circle to measure extracellular background. The background was 
subtracted from the average kinetochore-localized Kif18A fluorescence intensity to 
determine average Kif18A expression for each cell in each condition. 
Knockdown Quantification (RNA Levels) by qPCR 
Cells were plated at 200,000 cells per well in a 6-well plate and treated with either 
control or Kif18A. The cells were lysed 48 hours after siRNA treatment, and the RNA was 
extracted using an RNeasy extraction kit (Qiagen). The extracted RNA was diluted to 
250ng/uL, and the diluted samples were sent to the Vermont Integrative Genomics 
Resource core facility for quality control and qPCR. The samples were tested for RNA 
integrity and purity using a Bioanalyzer instrument prior to qPCR runs. Taqman probes 
(Thermo Fisher Scientific) specific for human GAPDH (endogenous control) and human 
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Kif18A were used to measure the levels of GAPDH and Kif18A RNA present in the 
samples. The number of qPCR cycles required to reach an RNA level threshold was 
recorded for both GAPDH and Kif18A. The number of cycles required for the Kif18A RNA 
levels to reach the threshold was normalized to the number of cycles required for GAPDH 
RNA levels to reach the threshold so that the expression of Kif18A mRNA is always 
relative to an endogenous control.   
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Results 
Kif18A is necessary for the mitotic progression and proliferation of TNBC cells but 
not for normal cells  
Two chromosomally unstable TNBC cell lines (MDA-MB-231 and MDA-MB-468) 
and a normal, chromosomally stable human breast epithelial cell line (MCF10A) were 
screened for proliferation defects upon siRNA knockdown (KD) of four different kinesin 
motor proteins (Kif18A, Kif4A, KID, and MCAK). A scrambled sequence was used for a 
control knockdown. MDA-MB-231 and MDA-MB-468 cell lines showed significantly 
reduced cell proliferation upon knockdown of Kif18A, while MCF10A cells showed no 
proliferation defect upon Kif18A depletion (Figure 4). None of the cell lines were affected 
by the KID or Kif4A knockdowns. Interestingly, depleting TNBC cell lines of MCAK 
increased their proliferation, while this same effect was not observed in the MCF10A cells. 
Immunofluorescence imaging of all three cell lines with- and without the kinesin 
knockdowns showed that Kif18A inhibition increased the mitotic index, or the proportion 
of cells in mitosis compared to interphase, for the two TNBC cell lines. The mitotic index 
is an indirect measure of how well a population of cells can progress through mitosis; the 
high mitotic index seen in Kif18A-depleted TNBC cells indicates that the cells are either 
taking longer to progress through mitosis or unable to complete mitosis. Kif18A had no 
effect on the mitotic index of the MCF10A cells, and none of the other kinesins had an 
effect on the mitotic index of any of the three cell lines.  
Some colorectal cancer cell lines require Kif18A for proliferation 
After determining that Kif18A is required for the proliferation of TNBC cells, 
additional cell proliferation assays were conducted on colorectal cancer cell lines to 
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determine whether these results were TNBC-specific or whether they could be applicable 
to other types of cancers. High Kif18A expression has been linked to increased cell growth 
in colorectal cancer [11]. To determine if depletion of Kif18A would also cause a growth 
defect in colorectal cancer, the effects of Kif18A inhibition on the proliferation of four 
colorectal cancer cell lines (HT29, LS1034, LoVo, and HCT116) were investigated. HT29 
and LS1034 cells display chromosomal instability, while LoVo and HCT116 cells are 
chromosomally stable but contain damaged DNA from microsatellite instability. Kif18A 
inhibition in HT29 cells caused a proliferation defect, but the three other CRC cell lines 
were not significantly affected by the Kif18A knockdown (Figure 5). This indicates that 
Kif18A dependence is not based on which part of the body the cancer originates from, 
but rather is likely based on a particular genomic characteristic of the cancer cells.  
Endogenous Kif18A levels and Kif18A knockdown efficiency were not correlated 
with cell-specific Kif18A sensitivity 
One possibility for varying Kif18A dependency in these cancer cell lines is an 
inconsistency in Kif18A knockdown efficiency across different cell types. To rule out 
differences in knockdown efficiency as a cause of cell-specific sensitivity to Kif18A 
inhibition, Kif18A mRNA levels were measured via qPCR for populations of cells treated 
with either Kif18A siRNA or a scrambled sequence control siRNA. The results of the 
qPCR show that the HT29 cells have the highest amount of Kif18A mRNA left after the 
knockdown (69.2 ± 10% remaining Kif18A mRNA) (Figure 6). The MDA-MB-231, 
HCT116, and MCF10A cells had 13.9 ± 1%, 11.6 ± 1.3%, and 18.0 ± 2.5% remaining 
Kif18A mRNA after the knockdown, indicating that the lack of proliferation defect upon 
Kif18A inhibition in MCF10A and HCT116 cells is not due to an insufficient Kif18A 
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knockdown. To investigate the high levels of Kif18A remaining in HT29 cells, the 
knockdown was assessed on the protein level via immunofluorescence imaging. Through 
this method, it was found that there was 34.5 ± 21.9% of Kif18A protein remaining in the 
HT29 cells after the knockdown, suggesting that the knockdown is more effective than 
indicated by the qPCR results.  
Endogenous Kif18A mRNA levels were analyzed by normalizing Kif18A mRNA 
levels to GAPDH mRNA levels within untreated populations of cells via qPCR. All cell 
lines were normalized to the levels of Kif18A mRNA in MDA-MB-231 cell, which contained 
the highest levels of endogenous Kif18A mRNA (Figure 7). Relative to MDA-MB-231 
endogenous Kif18A mRNA expression levels, HT29 and HCT116 cells contained 75.9 ± 
13.1% and 81.0 ± 6.4%. The normal breast cells, MCF10As, contained 23.1 ± 3.6% 
Kif18A mRNA compared to the MDA-MB-231 cells. These results suggest that cancer 
cells have higher Kif18A expression levels than normal human cells, which has been 
previously indicated in several clinical studies [11,12]. The high expression of Kif18A 
mRNA in HCT116 cells indicates that Kif18A expression is not a determining factor in 
whether or not a cell line requires Kif18A to proliferate, as HCT116 cells proliferate 
normally in the absence of Kif18A.  
Cells with a proliferation dependence for Kif18A have a higher incidence of 
multipolar spindles 
Once Kif18A knockdown efficiency was ruled out for cancer cell type differences 
in cellular proliferation, we sought to determine the underlying mechanism driving these 
effects. To identify mechanisms behind why some cancer cell types are more sensitive to 
Kif18A inhibition, I looked closer at the spindle architecture in HT29 and MDA-MB-231 
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cells, the cell types most dependent on Kif18A for cell proliferation in colorectal and breast 
cancer respectively. HT29 and MDA-MB-231 cells were treated with Kif18A and control 
siRNAs, then fixed and stained as previously described for immunofluorescence imaging 
of the microtubules and spindle poles. As was expected from previous results, Kif18A-
depleted populations of these cancer cell types had significantly higher proportions of 
cells in mitosis than control cells. Interestingly, these cancer cell types depleted of Kif18A 
showed a high incidence of multipolar spindles within the population of cells (Figure 10). 
Previous research has shown that the overexpression of Kif18A causes an increased 
incidence of multipolar spindles as well [9]. It is unclear whether Kif18A has a direct 
influence on the integrity of spindle poles, or whether mitotic arrest-induced pole splitting 
occurs as a result of the knockdown.  
Kif18A halts mitotic progression in CIN colorectal cancer cell lines but not in MSI 
colorectal cancer cell lines 
To determine what a disruption of spindle architecture might cause in the mitotic 
process of these cancer cell types, HT29 and HCT116 cells were imaged live for 16 hours 
with 2-minute time resolution. The time between nuclear envelope breakdown and 
anaphase entry was recorded as the mitotic timing. This imaging revealed that while the 
majority of HT29 control cells (60%) have a mitotic timing between 10 to 100 minutes, the 
majority of HT29 cells with the Kif18A knockdown (67 ± 6.3%) fail to exit mitosis (Figure 
11). While HCT116 Kif18A knockdown cells had slightly longer mitotic timings than 
HCT116 control cells (87.8 minutes for the knockdown condition and 64.1 minutes for the 
control), there were no HCT116 cells in either condition that failed to complete mitosis. 
These findings suggest that some cell lines may take slightly longer to organize and 
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segregate their chromosomes during mitosis without Kif18A, while other cell lines require 
Kif18A to surpass the spindle assembly checkpoint that promotes anaphase onset.  
Kif18A dependency correlates with chromosome copy number 
One intriguing possibility for these Kif18A mechanistic dependencies is that Kif18A 
is only essential for forward progression through mitosis when there are more than the 
normal number of chromosomes present in the cell. To determine if there is a correlation 
between chromosome copy number and proliferation defect, cell lines were plotted on a 
graph based on their documented modal chromosome number and the normalized fold 
change of their proliferation with the Kif18A knockdown (Figure 8). This graph showed a 
strong correlation between high modal chromosome number and sensitivity to the Kif18A 
knockdown, indicating that CIN cancer cells may be more dependent on Kif18A than MSI 
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Discussion 
These data suggest that Kif18A may have potential as a minimally-harmful target 
for TNBC therapy and some CRC therapy. After measuring the proliferation rates and 
mitotic progression of TNBC and CRC cells after a Kif18A knockdown, it is clear that there 
are differences in how specific cancer cell types are affected by the knockdown. High 
modal chromosome number was correlated with a greater reduction in proliferation and 
a longer mitotic timing upon Kif18A knockdown. Since none of the MSI cell lines or the 
normal cell line examined in this study were affected by the knockdown, chromosomal 
instability may be a necessary factor for Kif18A-dependence. It is important to note, 
however, that not all of the CIN lines tested in this study had reduced proliferation as a 
result of the Kif18A knockdown; thus, there must be other molecular characteristics that 
influence a cell’s Kif18A-dependence along with chromosomal instability. Future research 
could include additional qPCR looking at Kif18A-knockdown cells for changes in the 
expression levels of mRNA transcripts for proteins such as Hec1, Aurora A kinase, and 
others involved in mitotic progression and spindle architecture. Additionally, qPCR could 
be utilized to look for overexpression of other mitotic kinesins that may help some cells 
compensate for a loss of Kif18A.  
One hypothesis for why CIN cells are particularly reliant on Kif18A to proliferate is 
that aneuploid cells, or cells with abnormal numbers of chromosomes, may be faced with 
structural challenges while aligning and separating their chromosomes during mitosis. Dr. 
Jason Stumpff has previously proposed this concept as the “fragile spindle model.” This 
model states that unbalanced forces present during mitosis due to chromosomal 
instability may result in a “fragile” spindle that heavily relies on the strict regulation of 
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mitotic processes. Without proper regulation of microtubule dynamics via Kif18A, these 
cells may accumulate kinetochore-microtubule attachment defects that would prevent the 
progression of mitosis via activation of the spindle assembly checkpoint. Further 
investigation of this hypothesis should involve a closer look at the mechanisms of Kif18A 
in the mitotic progression of CIN cell lines. Specifically, the processes behind Kif18A 
knockdown-induced mitotic arrest should be studied to better understand why Kif18A is 
necessary for some CIN cell lines but not all CIN cell lines.  
Previous research from the Stumpff Lab has shown that Kif18A interacts with 
protein phosphatase 1 (PP1) to facilitate dephosphorylation of Hec1, which is a crucial 
step involved in mitotic progression [8]. Dephosphorylation of Hec1 inactivates the mitotic 
spindle assembly checkpoint, allowing cells to continue through to anaphase. Future 
experiments could involve inhibiting Kif18A in cells and subsequently transfecting the 
cells with a mutant form of Kif18A containing a non-functional PP1-binding domain. 
Certain assays conducted in this study – including the mitotic timing assay, the 
proliferation assay, and fixed cell imaging – could be repeated using these transfected 
cells to assess how the PP1-binding ability of Kif18A affects mitotic progression, 
multipolar spindle formation, and cell proliferation. This may help to isolate distinct 
functions of Kif18A so that its role in mitotic spindle mechanics may be better defined.  
Another interesting avenue for future studies could include investigating the 
observed increase in multipolar spindles upon Kif18A inhibition. Determining whether 
multipolar spindle formation is a direct product of the Kif18A knockdown or whether it is 
caused by the induced mitotic arrest may be important for further assessment of Kif18A 
as a therapeutic cancer target. Preliminary experiments have been conducted to indicate 
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whether the inhibition of the mitotic spindle assembly checkpoint in Kif18A knockdown 
cells rescues the increased incidence of cells with multipolar spindles (Figure 12). 
Inhibition of Mad2, an essential protein in the spindle assembly checkpoint, in 
combination with Kif18A inhibition provides a model of how Kif18A-depleted cells would 
behave in the absence of the spindle assembly checkpoint. The preliminary results of 
these experiments in HT29 and MDA-MB-231 cells suggest that the increased incidence 
of cells with multipolar spindles may not be fully rescued by the inhibition of the spindle 
assembly checkpoint. This would indicate that Kif18A knockdown-induced multipolar 
spindles are not caused by a mitotic arrest, but that Kif18A has a more direct influence 
on spindle pole integrity. Further biological replicates are needed for these experiments 
before any conclusions can be drawn.  
Finally, while this this study focused solely on colorectal cancer and triple negative 
breast cancer, there is compelling evidence that Kif18A should be assessed as a potential 
therapeutic target for other types of cancers as well. Kif18A overexpression has been 
previously indicated in multiple myeloma, ovarian cancer, glioblastoma, and lung 
adenocarcinoma [13,14,16,20]. Higher Kif18A expression in lung adenocarcinoma has 
been correlated to poorer overall survival and an increase in cancer recurrence [20]. In 
glioblastoma patients, upregulation of Kif18A in glioblastoma stem cells has been linked 
to poorer overall survival, indicating that Kif18A may have a role as a cancer driver in 
these cells [16]. Conversely, Kif18A expression appears to be downregulated in gastric 
cancer tissue, with lower expression levels correlating to worse prognosis [18]. More 
research is needed to determine the role of Kif18A in the progression and outcome of 
these aforementioned cancer types. 
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Overall, it is clear that Kif18A is a promising candidate for future targeted 
approaches to treat triple negative breast cancer and colorectal cancer. The results of 
this study support the continuation of investigating the potential of Kif18A in these cancers 
and in other types of cancers. Through new knowledge of Kif18A’s role in cancer 
progression, we may be able to develop novel strategies for the prevention, diagnosis, 
and treatment of aggressive cancers.   






Figure 1: Diagram of nuclear receptor differences between most breast cancers and 
TNBC 
TNBC is a particularly aggressive form of breast cancer because of its lack of estrogen 
receptors (ER), progesterone receptors (PR), and the overexpression of the HER2 receptor. 
These nuclear receptors are often targeted in breast cancer therapy, so their absence in 
TNBC enables cancer cells to evade most targeted breast cancer therapies. Researching 
new molecular targets for TNBC is therefore of paramount importance.   
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Figure 2: Proliferation assay validation 
Two cell lines of differing cell size (HCT116 and CaCo2) were imaged using high contrast 
bright field (HCBF) microscopy and fluorescence microscopy with a nuclear Hoechst stain. 
Cell counts were compared between the HCBF automated counts and the Hoechst stain 
counts at different cell densities and for cells treated with either control siRNA or Kif18A 
siRNA. Yellow outlines in the bottom panels indicate the cells counted by the software. There 
were no significant different between the number of cells counted using HCBF and Hoechst 
stain across different densities and across the two treatment conditions.   
 
  




Figure 3: Proliferation assay kinetics 
(Bottom) Images of colorectal cancer cells multiplying during a 6-day (144 hour) proliferation 
assay at times: 34 hours, 64 hours, 76 hours, and 130 hours. (Top) Example trace of cell 
confluence over 144 hours measured by Gen5 software, with different colors representing a 
variety of treatment conditions.   





Figure 4: Kinesin knockdown panels for TNBC and normal breast epithelial cells  
Two TNBC cell lines (MDA-MB-468 and MDA-MB-231) and a normal human breast epithelial 
cell line (MCF10A) were treated with siRNA to deplete the cells of four different kinesins: 
Kif18A, Kif4A, KID, and MCAK. Depletion of Kif18A caused a decrease in the proliferation of 
both types of TNBC cells and caused an increase in the mitotic index, or the proportion of 
cells in mitosis compared to interphase. None of the kinesin knockdowns affected the 
proliferation or mitotic index of the MCF10A cells. One-way ANOVA with post-hoc Tukey’s 
test was used for all comparisons. ****= p<0.0001, **= p<0.01, * = p<0.05 
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Cell Line  Cancer Type CIN Status (+/-) MSI Status (+/-) 
MDA-MB-231  TNBC + - 
MDA-MB-468  TNBC + - 
LoVo  CRC - + 
SW480  CRC + - 
HT-29  CRC + - 
HCT-116  CRC - + 
LS1034 CRC + - 
MCF10A N/A - - 
 
Table 1: Cell lines included in the study 
Shaded based on cancer type; unshaded for non-cancer cell lines. CIN = chromosomal 
instability; MSI = microsatellite instability  
 
  





Figure 5: Proliferation of cancer cells with Kif18A Inhibition   
Cells were treated with either control or Kif18A siRNA and imaged using high 
contrast brightfield microscopy every two hours for 120 hours. Proliferation rates were 
quantified as the normalized fold change in the number of cells per square millimeter in each 
well. Unpaired t-tests were used to determine statistical significance. Error bars represent the 
standard deviation. (A-C) Two TNBC cell lines, MDA-MB-231 and MDA-MB-468, and one 
CRC cell line, HT29, showed significantly decreased proliferation rates upon Kif18A inhibition. 
(D-F) Three CRC cell lines, LoVo, HCT116, and LS1034, did not show markedly reduced 
proliferation upon Kif18A inhibition. **** = p < 0.0001  
 
  









Figure 6: Kif18A knockdown quantification at the RNA and protein level 
(A) Kif18A RNA levels were measured in two cell lines that had reduced proliferation rates 
upon Kif18A-knockdown (MDA-MB-231 and HT29) and two cell lines that showed no 
proliferation defect upon Kif18A-knockdown (HCT116 and MCF10A). GAPDH was used as 
an endogenous control; the percentage of Kif18A RNA remaining in the cell population is 
relative to the amount of GAPDH present in the cells. (B) HT29 cells were fixed onto 
coverslips 48 hours after Kif18A KD and stained for Kif18A. The average fluorescence 
intensity of Kif18A GFP signal with the background signal subtracted out was compared 
between the control and Kif18A knockdown. (C) Example of Kif18A knockdown in MDA-MB-
231 cells stained for kinetochores (ACA), Kif18A, and microtubules (Alpha Tubulin).   
**** = p < 0.0001 
  






Figure 7: Endogenous Kif18A mRNA levels across multiple cell lines  
Kif18A mRNA levels were assessed by qPCR of untreated cells from each of four cell lines. 
All three cancer cell lines (MDA-MB-231, HT29, HCT116) had significantly higher 
endogenous Kif18A levels than the normal breast epithelial cells (MCF10A). Since HCT116 
cells show no proliferation defect upon Kif18A knockdown, this indicates that endogenous 
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Kif18A Knockdown Quantification by 
qPCR 
Cell Line Percent Kif18A 
mRNA Remaining 
MDA-MB-231 13.9 ± 1% 
HT29 69.2 ± 10% 
HCT116 11.6 ± 1.3% 









Quantification of Endogenous Kif18A RNA Expression 






100 ± 6.6% 75.9 ± 13.1% 81.0 ± 6.4% 23.1 ± 3.6% 
 
 
Table 2: Compilation of knockdown quantifications and endogenous Kif18A RNA 
expression levels 
Tables showing the numeric values of the Kif18A knockdown quantification by qPCR (Top) 
and by immunofluorescence imaging (Middle). (Bottom) Measures of the endogenous 
Kif18A RNA levels in untreated cells.   
 
Kif18A Knockdown Quantification by 
Immunofluorescence 
Cell Line Percent Kif18A 
Protein Remaining 
HT29 34.5 ± 21.9% 





Figure 8: Modal chromosomal number correlates to cell proliferation defect upon 
Kif18A-knockdown  
The modal chromosome number, or the average number of chromosomes within a cell line, 
was plotted against the normalized fold change in proliferation of Kif18A-knockdown cells 
compared to control cells. Cell lines with modal chromosome numbers near 48 (the normal 
modal number for healthy somatic cells) are less affected by the Kif18A knockdown than 
those with higher numbers of chromosomes. This indicates that polyploidy and chromosomal 





























Kif18A KD Proliferation Rates vs. 
Modal Chromosome Number
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Figure 9: Multipolar spindles form as a result of Kif18A knockdown in HT29 cells 
Immunofluorescence imaging of HT29 control and Kif18A knockdown cells revealed an 
increase in the number of cells with multipolar mitotic spindles (those with three or more 
poles). (Top) Spindle poles (centrosomes) are marked by bright spots of gamma tubulin; 
alpha tubulin represents microtubules; ACA signal represents kinetochores. (Bottom) 
Representative field of Kif18A knockdown HT29 cells, with four multipolar cells and one 
bipolar cell.  
  




Figure 10: CIN cell lines display an increase in the number of cells with multipolar 
spindles upon Kif18A KD 
Two CIN cell lines (HT29 and MDA-MB-231) and one non-CIN, non-cancerous cell line 
(MCF10A) were imaged using immunofluorescence microscopy to visualize the structural 
features of mitosis, including the centrosomes (spindle poles) and microtubules. The two CIN 
cell lines both showed a significant increase in the number of cells with multipolar spindles 
after the Kif18A knockdown, while the non-CIN normal human cells showed no increase in 
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Figure 11: Mitotic timing of HCT116 and HT29 cells with and without a Kif18A 
knockdown 
One CIN cell line (HT29) and one non-CIN cell line (HCT116) were treated with Kif18A siRNA 
and imaged 24 hours later using differential interference contrast (DIC) microscopy. Images 
were taken every two minutes over 16 hours. Mitotic timing was quantified as the time 
between nuclear envelope breakdown and anaphase formation. (A) Over 50% of HCT116 
control cells had a mitotic timing between 10 to 40 minutes, with smaller proportions of the 
cells taking between 40 to 100 minutes and more than 100 minutes. Only 35.2% of HCT116 
Kif18A KD cells had mitotic timings between 10 to 40 minutes, with slightly higher proportions 
of these cells taking longer to complete mitosis. (B) HT29 cells with the Kif18A KD had a 
higher proportion of cells fail to exit mitosis compared to the control, with very few Kif18A KD 
cells completing divisions in less than 40 minutes. (C) HT29 control cell completing mitosis in 
approximately 30 minutes. (D) HT29 Kif18A KD cell failing to exit mitosis within 80 minutes.  
  





Figure 12: Preliminary analysis of Kif18A knockdown on cells deficient of a functioning 
spindle assembly checkpoint 
HT29 and MDA-MB-231 cells were treated with a either control, Kif18A, Mad2, or a 
combination of Kif18A and Mad2 siRNA. Cells were fixed and stained 48 hours after siRNA 
treatment and imaged using immunofluorescence microscopy to visualize spindle poles. For 
both cell lines, the Kif18A knockdown in cells deficient of a functioning spindle assembly 
checkpoint (ie. cells with inhibited Mad2) resulted in a slight reduction in the number of cells 
with multipolar spindles compared to the Kif18A knockdown alone. In MDA-MB-231 cells, the 
Kif18A and Mad2 double knockdown resulted in significantly higher numbers of multipolar 
spindles compared to the control. While a similar trend was observed in the HT29 cells, it was 
not significant. One-way ANOVA post-hoc Tukey’s test was used for all comparisons was 
used to compare multipolar spindle counts between each condition. More biological replicates 
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